U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. AUCATZYL
  1. Vaccines, Blood & Biologics

STN: 125813
Proper Name: obecabtagene autoleucel
Tradename: AUCATZYL
Manufacturer: Autolus Limited
Indication:

  • For the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Product Information

  • Package Insert - AUCATZYL
  • Demographic Subgroup Information – obecabtagene autoleucel [AUCATZYL]
    Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.

Supporting Documents

Back to Top